Hepatoprotective potential of a novel quinazoline derivative in thioacetamide-induced liver toxicity
Open Access
- 20 September 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 943340
Abstract
Purpose: The compound quinazoline Q-Br, 3-(5-bromo-2-hydroxybenzylideneamino)-2-(5-bromo-2 hydroxyphenyl) 2,3-dihydroquinazoline-4(1H)-one (Q-Br) was evaluated for its antioxidant capacity and potential hepatoprotectivity against sub-chronic liver toxicity induced by thioacetamide in rats.Materials and Methods: Rats were assigned into five groups; healthy (normal) and cirrhosis control groups were given 5% Tween 20 orally, the reference control group was given a Silymarin dose of 50 mg/kg, and low-dose Q-Br and high-dose Q-Br groups were given a daily dose of 25 mg/kg and 50 mg/g Q-Br, respectively. Liver status was detected via fluorescence imaging with intravenous injection of indocyanine green (ICG) and a plasma ICG clearance test. Liver malondialdehyde (MDA), catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) were also tested. The degree of fibrosis was determined histologically by hematoxylin and eosin and Masson’s Trichrome staining. The immunohistochemistry of liver tissue inhibitor of metalloproteinase (TIMP-1), matrix metalloproteinase (MMP-2), and alpha-smooth muscle actin (α-SMA) was performed.Results: Q-Br recorded mild antioxidant capacity, dose-dependent improvement in the liver status, and inhibition of oxidative stress compared to cirrhosis control. Histopathology notified a remarkable reduction in the degree of fibrosis. Immunohistochemistry revealed an obvious low expression of MMP-2 and α-SMA along with a higher expression of TIMP-1 in Q-Br- and Silymarin-treated livers.Conclusion: Q-Br treatment altered the course of toxicity induced by thioacetamide suggesting significant hepatoprotective potential of Q-Br treatment.Keywords
This publication has 47 references indexed in Scilit:
- Hepatoprotective effect of ethanolic extract of Curcuma longa on thioacetamide induced liver cirrhosis in ratsBMC Complementary and Alternative Medicine, 2013
- Indocyanine green clearance test (using spectrophotometry) and its correlation with Model for End Stage Liver Disease (MELD) score in Indian patients with cirrhosis of liverTropical Gastroenterology, 2012
- Efficacy ofBoesenbergia rotundaTreatment against Thioacetamide-Induced Liver Cirrhosis in a Rat ModelEvidence-Based Complementary and Alternative Medicine, 2012
- Distribution of Hepatic Myofibroblasts and Type I and III Collagen in Rat Liver Cirrhosis Induced by ThioacetamideInternational Journal of Morphology, 2011
- Evolving challenges in hepatic fibrosisNature Reviews Gastroenterology & Hepatology, 2010
- The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 ActivityDrug Metabolism and Disposition, 2008
- Curcumin: potential for hepatic fibrosis therapy?British Journal of Pharmacology, 2008
- MELATONIN PRETREATMENT IMPROVES LIVER FUNCTION AND HEPATIC PERFUSION AFTER HEMORRHAGIC SHOCKShock, 2008
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Assessment of liver function in chickens using galactose and indocyanine green clearancesAvian Pathology, 2000